|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C4A |
Gene summary for C4A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C4A | Gene ID | 720 |
| Gene name | complement C4A (Rodgers blood group) | |
| Gene Alias | C4 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | P0C0L4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 720 | C4A | S014 | Human | Liver | HCC | 3.64e-16 | 5.83e-01 | 0.2254 |
| 720 | C4A | S015 | Human | Liver | HCC | 1.31e-05 | 2.94e-01 | 0.2375 |
| 720 | C4A | S016 | Human | Liver | HCC | 3.39e-08 | 2.64e-01 | 0.2243 |
| 720 | C4A | S027 | Human | Liver | HCC | 9.18e-07 | 6.14e-01 | 0.2446 |
| 720 | C4A | S028 | Human | Liver | HCC | 4.40e-18 | 4.44e-01 | 0.2503 |
| 720 | C4A | S029 | Human | Liver | HCC | 3.57e-22 | 7.57e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00423032 | Prostate | BPH | molting cycle | 28/3107 | 107/18723 | 7.85e-03 | 3.43e-02 | 28 |
| GO:00426332 | Prostate | BPH | hair cycle | 28/3107 | 107/18723 | 7.85e-03 | 3.43e-02 | 28 |
| GO:004603419 | Prostate | Tumor | ATP metabolic process | 122/3246 | 277/18723 | 1.71e-25 | 5.33e-22 | 122 |
| GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
| GO:001049819 | Prostate | Tumor | proteasomal protein catabolic process | 158/3246 | 490/18723 | 3.05e-16 | 6.76e-14 | 158 |
| GO:000206418 | Prostate | Tumor | epithelial cell development | 88/3246 | 220/18723 | 1.30e-15 | 2.38e-13 | 88 |
| GO:000989619 | Prostate | Tumor | positive regulation of catabolic process | 155/3246 | 492/18723 | 5.62e-15 | 8.52e-13 | 155 |
| GO:003133119 | Prostate | Tumor | positive regulation of cellular catabolic process | 134/3246 | 427/18723 | 5.54e-13 | 5.84e-11 | 134 |
| GO:004316119 | Prostate | Tumor | proteasome-mediated ubiquitin-dependent protein catabolic process | 130/3246 | 412/18723 | 7.97e-13 | 8.00e-11 | 130 |
| GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
| GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
| GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
| GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
| GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
| GO:000913216 | Prostate | Tumor | nucleoside diphosphate metabolic process | 46/3246 | 124/18723 | 1.15e-07 | 3.01e-06 | 46 |
| GO:000918517 | Prostate | Tumor | ribonucleoside diphosphate metabolic process | 41/3246 | 106/18723 | 1.47e-07 | 3.72e-06 | 41 |
| GO:000913518 | Prostate | Tumor | purine nucleoside diphosphate metabolic process | 39/3246 | 103/18723 | 5.60e-07 | 1.19e-05 | 39 |
| GO:000917918 | Prostate | Tumor | purine ribonucleoside diphosphate metabolic process | 39/3246 | 103/18723 | 5.60e-07 | 1.19e-05 | 39 |
| GO:004693916 | Prostate | Tumor | nucleotide phosphorylation | 37/3246 | 101/18723 | 2.73e-06 | 4.54e-05 | 37 |
| GO:000854415 | Prostate | Tumor | epidermis development | 89/3246 | 324/18723 | 3.15e-06 | 5.18e-05 | 89 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa049362 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa051332 | Liver | HCC | Pertussis | 48/4020 | 76/8465 | 4.17e-03 | 1.27e-02 | 7.06e-03 | 48 |
| hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa049363 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa051333 | Liver | HCC | Pertussis | 48/4020 | 76/8465 | 4.17e-03 | 1.27e-02 | 7.06e-03 | 48 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| C4A | C3AR1 | C4A_C3AR1 | COMPLEMENT | Endometrium | Healthy |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C4A | SNV | Missense_Mutation | novel | c.2544G>C | p.Gln848His | p.Q848H | P0C0L4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| C4A | SNV | Missense_Mutation | novel | c.4115N>T | p.Gly1372Val | p.G1372V | P0C0L4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A12L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C4A | SNV | Missense_Mutation | rs767169624 | c.3442G>A | p.Ala1148Thr | p.A1148T | P0C0L4 | protein_coding | deleterious(0) | possibly_damaging(0.666) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C4A | SNV | Missense_Mutation | novel | c.3526N>C | p.Asn1176His | p.N1176H | P0C0L4 | protein_coding | tolerated(0.21) | benign(0.059) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C4A | SNV | Missense_Mutation | rs749075087 | c.3179N>A | p.Arg1060Gln | p.R1060Q | P0C0L4 | protein_coding | tolerated(0.52) | probably_damaging(0.983) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| C4A | SNV | Missense_Mutation | c.3604N>G | p.Leu1202Val | p.L1202V | P0C0L4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| C4A | SNV | Missense_Mutation | c.2695N>C | p.Phe899Leu | p.F899L | P0C0L4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-4005-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | CR | |
| C4A | SNV | Missense_Mutation | rs370461806 | c.2758G>A | p.Glu920Lys | p.E920K | P0C0L4 | protein_coding | tolerated(0.11) | benign(0.093) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C4A | SNV | Missense_Mutation | novel | c.4137N>T | p.Lys1379Asn | p.K1379N | P0C0L4 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C4A | SNV | Missense_Mutation | novel | c.2509N>A | p.Leu837Ile | p.L837I | P0C0L4 | protein_coding | deleterious(0.01) | possibly_damaging(0.675) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |